| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2137691 | Leukemia Research | 2010 | 6 Pages |
Abstract
2CdA therapy is effective in the treatment of MZL. Adding rituximab allows increasing ORR and CR, prolonging TTF.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Enrico Orciuolo, Gabriele Buda, Elisabetta Sordi, Claudia Baraté, Sara Galimberti, Eugenio Ciancia, Mario Petrini,